Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DCVax-Direct for Brain Metastases from Breast or Lung Cancer
NCT03638765Phase 1Unknown
- Sponsor
- Northwest Biotherapeutics
- Start
- Nov 2018
- Primary completion
- Dec 2019
- Modality
- Whole Cell Cancer Vaccines, Dendritic Cell Vaccines
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of dcvax-direct in brain metastases, breast cancer and non-small cell lung cancer (NSCLC), sponsored by Northwest Biotherapeutics. Primary endpoint: Overall incidence of adverse events. Status: unknown.
02
Drugs
dcvax-direct
03
Conditions
brain metastasesbreast cancernon-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03638765.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03638765.